Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Hepatology

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Clin Gastroenterol Hepatol

Vidal-Trécan T, Julla JB, El Khoury T, Venteclef N, Riveline JP, Paradis V, Valla D, Gautier JF, Castera L

doi: 10.1016/j.cgh.2025.02.018

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Hepatology

Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence

J Gastroenterol Hepatol

Chen Y, Zhai D, Shen J, Hu W

doi: 10.1111/jgh.70003

Hepatology

Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort

Am J Gastroenterol

Perez-Diaz-Del-Campo N, Castelnuovo G, Ferro A, Caviglia GP, Rosso C, Dileo E, Guariglia M, Armandi A, Saba F, Saracco GM, Barutta F, Beccuti G, Gruden G, Younossi ZM, Bugianesi E

doi: 10.14309/ajg.0000000000003594

Inflammatory Bowel Disease

Risk of age-related and disease-related complications and mortality in elderly-onset IBD - a population-based study

Clin Gastroenterol Hepatol

Ben Hur D, Issaschar G, Moshe R, Lebedenko B, Lujan R, Haklai Z, Weisband YL, Ben-Tov A, Lederman N, Matz E, Dotan I, Turner D, Pinto GD, Waterman M

doi: 10.1016/j.cgh.2025.01.020

Colonoscopy

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Endoscopy

van Roermund NS, van Leerdam ME, Spaander MCW, Dekker E, IJspeert JEG

doi: 10.1055/a-2730-6060

Hepatology

Association between longitudinal weight change and clinical outcome in individuals with MASLD

Hepatology

Shi Y, Zhou R, Kim SU, Yip TC, Tsochatzis E, Petta S, Nakajima A, Hagström H, Bugianesi E, Chan WK, Boursier J, Goh BG, Sanyal AJ, Romero-Gomez M, Calleja JL, Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Fournier-Poizat C, Lee HW, Wong GL, Pennisi G, Yoneda M, Shang Y, Armandi A, de Saint-Loup M, Canivet CM, Teh KK, Asgharpour A, Gallego-Durán R, Llop E, Lara-Romero C, Sau-Wai Chan M, Zoncape M, Lin H, Liu WY, Targher G, Byrne CD, Wong VW, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1097/HEP.0000000000001557

Related content

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence

Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort

Risk of age-related and disease-related complications and mortality in elderly-onset IBD - a population-based study

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Association between longitudinal weight change and clinical outcome in individuals with MASLD